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Abstract: 
Background: The single-centre double-blind, randomised controlled Managing Asthma in 
Pregnancy (MAP) trial in Newcastle, Australia, compared a treatment algorithm using the 
fraction of exhaled nitric oxide (FeNO) in combination with asthma symptoms (FeNO group) 
against a treatment algorithm using clinical symptoms only (clinical group) in pregnant 
asthmatic women (ANZ Clinical Trials Registry, number 12607000561482). The primary 
outcome was a 50% reduction in asthma exacerbations during pregnancy in the FeNO group. 
However, the effect of FeNO-guided management on the development of asthma in the 
offspring is unknown.  
Objective: We sought to investigate the effect of FeNO-guided asthma management during 
pregnancy on asthma incidence in childhood.Methods: 179 mothers consented to 
participate in the Growing Into Asthma (GIA) double-blind follow-up study with the primary 
aim to determine the effect of FeNO-guided asthma management on childhood asthma 
incidence. Results: 140 children (78%) were followed up at 4 to 6 years of age. FeNO-guided 
as compared to symptoms only based approach significantly reduced doctor diagnosed 
asthma (25·9% versus 43·2%; odds ratio [OR] 0.46, 95% confidence interval [CI] 0.22 to 
0.96, p=0.04). Furthermore frequent wheeze (OR 0.27; CI 0.09 to 0.87, p=0.03), use of short-
acting beta agonists (OR 0.49; CI 0.25 to 0.97; p=0.04), and emergency department visits for 
asthma (OR 0.17, CI 0.04 to 0.76; p=0.02) in the past 12 months were less common in 
children born to mothers from the FeNO group. Doctor diagnosed asthma was associated 
with common risk alleles for early-onset asthma at gene locus 17q21 (p=0·01 for rs8069176; 
p=0·03 for rs8076131), and higher airways resistance (p=0·02) and FeNO levels (p=0·03). A 
causal mediation analysis suggested natural indirect effects of FeNO-guided asthma 
management on childhood asthma through "any use" and "time to first change in dose" of 
inhaled corticosteroids during the MAP trial (OR 0.83; CI 0.59 to 0.99 and OR 0.90, CI 0.70 
to 1.03, respectively).Conclusion: FeNO-guided asthma management during pregnancy 
prevented doctor diagnosed asthma in the offspring at preschool age, in part mediated 
through changes in use and dosing of inhaled corticosteroids during the MAP trial.  
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Introduction: 
A history of maternal asthma remains among the most robust predictors of virus-induced 
lower respiratory tract infections in infancy, and childhood-onset asthma with an odds ratio of 
3.0 (95% confidence interval [CI], 2.6-3.6) for asthma in a pooled analysis of 33 studies(1). 
Surprisingly, the impact of asthma control, exacerbations and asthma management during 
pregnancy on the offspring’s asthma risk remains poorly studied. However, an increased risk 
for asthma has been reported in a retrospective case-control study of children whose mothers 
had moderate-to-severe uncontrolled asthma during pregnancy(2). Asthma during pregnancy 
may shape the future child’s future asthma risk trajectory via an interaction between 
heritability and in utero exposures at the feto-maternal interface. Notably very common 
exposures such as asthma medications and exacerbations during pregnancy have not been 
investigated for an association with the child’s asthma risk.   
 
The Managing Asthma in Pregnancy (MAP) study was a double-blind randomised controlled 
trial (RCT) in asthmatic women(3). It compared the efficacy of a management algorithm that 
combined the non-invasive assessment of T helper 2 (TH2) cell cytokine (IL-4 and IL-13) 
induced airways inflammation by means of measuring the fractional exhaled nitric oxide 
(FeNO) and asthma symptoms (FeNO group) against a symptoms only based approach 
(clinical group). Total asthma exacerbations were reduced (incidence rate ratio 0.50, 95% CI 
0.33-0.76) in the FeNO group, compared to the clinical group(3). At the end of the study, 
more pregnant women took inhaled corticosteroids (ICS) and ICS plus long-acting beta 
agonists (ICS/LABA) -but in a lower mean ICS dose- in the FeNO group as a result of the 
treatment algorithm (68.5% versus 42.2%, p<0.0001 and 40.5% versus 17.4%, p<0.0001). In 
contrast, fewer women in the FeNO group as compared to the clinical group needed short 
acting beta agonist treatment in the last RCT week (median [interquartile range, IQR] 0 [0-3] 
days versus 1 [0-5] days, p=0.024). There were no differences in FeNO levels, FEV1 and 
FEV1% between the groups(3).  
During the MAP RCT, mothers were invited to have their offspring participate in the 
Growing into Asthma (GIA) birth cohort study. At 12 months of age, we conducted the first 
follow-up visit to investigate the parent-reported incidence of virus-induced wheezy lower 
respiratory tract infections (“bronchiolitis”). We found that infants born to mothers from the 
FeNO group had a reduced risk for recurrent bronchiolitis episodes in the first year of life 
(odds ratio [OR] 0.08, 95% confidence intervals [CI] 0.01-0.66)(4). Notably, the Childhood 
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Origins of Asthma (COAST) birth cohort of high-risk children born to parents with asthma or 
allergy reported an association between moderate-to-severe wheezy illnesses in the first three 
years of life and asthma by age six years. Odds ratios ranged between 2.6 (95% CI 1.0-6.3) 
for respiratory syncytial virus (RSV)–induced and 9.8 (95% CI, 4.3-22.0) for rhinovirus 
(RV)-induced wheezing illnesses(5). Furthermore a single nucleotide polymorphism (SNP) at 
a highly replicated asthma locus on chromosome 17q21 (rs7216389)(6) was associated with a 
genotype-specific risk for asthma only in children with a RV-induced wheezing illness in 
early life (p=0.004)(7). The ORM (yeast)-like protein isoform 3 (ORMDL3) protein, coded at 
the 17q21 locus, has been shown to be associated with a cellular stress response and release 
of pro-inflammatory molecules involved in airways remodelling and 
inflammation(8),(9),(10).  
The results from the COAST study in conjunction with our findings provided a strong 
rationale to prospectively test the hypothesis in the GIA cohort proposed earlier(4) that 
‘asthma in pregnancy is a potentially modifiable determinant in the prenatal origins of 
bronchiolitis with the prospect to be evaluated as a potential primary preventative strategy 
that could modulate the risk of childhood asthma’. The primary aim of the GIA study was to 
determine the effect of FeNO-guided asthma management during pregnancy on asthma 
incidence in childhood, and the secondary aim was to determine asthma-related symptoms 
and healthcare utilisation. In further explorative analyses, we aimed at investigating the role 
of ICS in mediating, and the relevance of 17q21 variants in modifying the effect of FeNO-
guided asthma management on childhood asthma. 
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Methods 
 
Study design and participants 
The GIA study is a prospective, longitudinal, observational birth cohort study following the 
offspring of women with asthma during pregnancy who participated in the MAP study, a 
double-blind RCT conducted in Newcastle, Australia (Australian and New Zealand Clinical 
Trials Registry, number 12607000561482)(3).  
Children were born from February 6, 2008, to November 25, 2010. 174 mothers with 179 
children (one set of triplets and 3 twins) were subsequently recruited to the GIA study, of 
whom 146 were assessed at 12 months (82% participation)(4) and 140 (78%) at 4 to 6 years 
of age (Supplement Fig 1). The predefined primary aim(4) of the follow-up at 4 to 6 years of 
age was to determine the effect of FeNO-guided asthma management during pregnancy on 
the incidence of childhood asthma. The mothers, children and all study personnel involved in 
the follow-up visits and collection of biosamples were blinded as to which treatment group 
the mother was allocated during pregnancy. The study was approved by the Hunter New 
England Health and University of Newcastle Human Research Ethics Committees (ref no 
12/06/20/4.03), and written informed consent was obtained before inclusion into the study.  
Procedures and outcomes in the MAP study 
The primary aim of the MAP study was to test the efficacy of a treatment algorithm using 
monthly FeNO measurements in combination with asthma symptoms (defined by asthma 
control questionnaire [ACQ](11),(12), FeNO group) against a symptoms only based approach 
(clinical group) for the adjustment of maintenance therapy with inhaled corticosteroids (ICS) 
with and without long-acting beta agonists in pregnant women with asthma. Eligible women 
were randomised before 22 weeks’ gestation, and those with uncontrolled asthma who were 
not using ICS as maintenance treatment (n=31) were started on budesonide (200 µg twice per 
day) before randomisation. Women using ICS continued with their current dose, delivered as 
budesonide turbuhaler (Astra Zeneca, North Ryde, NSW, Australia), with dose equivalence 
determined from guidelines. Women were reviewed monthly at the antenatal clinic until 
delivery. The research assistant collected data for the clinical symptoms, ACQ score, current 
treatments, FeNO, and forced expiratory volume in 1 s (FEV1) in both groups. A statistician 
applied the relevant algorithm, and sent the treatment recommendation to the research 
assistant in the antenatal clinic, who informed the participant. Participants were seen by an 
investigator (PG) in the antenatal clinic if their asthma remained uncontrolled despite being at 
maximum treatment level in the algorithm. Telephone assessments were done 2 weeks after 
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each clinic visit to assess symptoms and to encourage drug adherence. Maternal asthma 
exacerbations during pregnancy were defined as events for which the patient sought medical 
attention (an unscheduled visit to a doctor, presentation to the emergency room or admission 
to hospital, or when oral corticosteroids were used for treatment of asthma). All 
exacerbations that occurred after randomisation were recorded prospectively.  
Procedures and outcomes in the GIA study 
Questionnaires completed by the parent/carer were the ISAAC core questionnaire (wheezing, 
rhinitis and eczema modules for 6-7 year old children)(13) and additional standardised 
respiratory symptom questions validated for pre-schoolers(14, 15). A clinical examination of 
the child and standardised interview of the primary carer was conducted by a senior medical 
doctor (advanced trainee level in paediatrics or greater), to confirm the appropriateness of a 
doctor diagnosis of asthma in accordance with national asthma guidelines(16).  
Buccal swabs were collected for DNA extraction and atopy was defined as a positive 
response (≥3mm wheal) to any one of the common aeroallergens dermatophagoides 
pteronyssinus, dermatophagoides farinae, cat, dog, aspergillus fumigatus, 5 grass mix, and 
the standard food allergens whole peanut extract, egg yolk and egg white. Blood sample 
collection was offered as an opt-in investigation. 
Lung function measurement was attempted in all willing participants during attendance at the 
preschool age check-up. Multiple breath nitrogen washout (MBN2W) was performed using 
commercial MBN2W (Exhalyzer D, EcoMedics AG, Switzerland) in accordance with the 
consensus statement for inert gas washout measurements using multiple- and single-breath 
washout(17), and was successfully measured (at least two measurements with a coefficient of 
variance [CV] within 10%) in 99 out of 128 (77%) children who were willing to be tested. 
Impulse oscillometry (IOS) was conducted using a combined commercial system 
(MasterScreen system, Jaeger Co, Wuerzberg, Germany) and successful in 107/122 (88%). 
Successful measurement was classified as at least three measurements (CV within 10%) with 
a best coherence threshold ≥0.6 at 5Hz and ≥0.9 at 20Hz. Single breath FeNO was also 
performed according to ATS/ERS recommendations(18) in order to familiarise the child with 
the test procedure for future follow-up visits, even though the expiratory manoeuvre can be 
challenging at preschool age. We used the CLD88 instrument (EcoMedics AG, Switzerland) 
and acceptable measurements (at least two measurements with a CV within 5% or three 
measurements within 10%) were recorded in 51/125 (41%).  
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DNA extraction and genotyping of 17q21 variants 
DNA was successfully extracted from 139 of the 140 buccal swabs from participating 
children collected at one of the follow-up visits (either preschool or 12 month visit) using the 
Gentra Puregene Buccal Cell kit (QIAGEN). DNA concentration and quality were measured 
using a Nanodrop ND-1000 Spectrophotometer (Thermo Scientific).  
Five previously reported childhood onset asthma-associated single-nucleotide polymorphisms 
(SNPs) at locus 17q21 were genotyped (rs8069176, rs7216389, rs8076131, rs9303277, 
rs2290400). Genotyping was performed using the TaqMan (Applied Biosystems Inc) assays 
and previously described primers and probes(7),(19). Genotyping success rates were 100% 
for all variants. 
RNA extraction from PBMCs and measurement of ORMDL3 gene expression 
Five millilitres of whole blood was collected from 72 (51%) consenting children. PBMCs 
were isolated from whole blood samples using the LymphoprepTM separation protocol 
(Stemcell technologies). After PBMC isolation, cells were counted on a hemocytometer and 
resuspended in 10% FCS RPMI at 1x106cells/ml. Cells were plated into 96 well round 
bottom plates at 2x105/well and incubated at 37∘C for five days. Total mRNA was extracted 
using TRIzol (Ambion). All steps were performed according to manufacturer’s instructions.  
ORMDL3 and HPRT primers (Supplementary table 1) were obtained from Jomar 
Biosciences and qPCR was run using SYBR green (QIAGEN). ORMDL3 was successfully 
amplified in 71 out of 72 PBMC samples. Each qPCR reaction was run in duplicate and only 
duplicates with a coefficient of variance of less than 0.05 were included in the analysis. We 
quantified mRNA copies using cDNA standards for all genes. We normalised expression 
levels to the house-keeping gene HPRT. 
Statistical analysis 
Categorical measures were summarised using counts and percentages while continuous 
measures were summarised using means and standard deviations for normally distributed 
data, or alternatively medians and interquartile ranges. Data were analysed according to the 
treatment intervention group to which the mothers were randomised. Due to the very low 
amount of missing data we present a complete case analysis under the missing completely at 
random assumption. Statistical significance for continuous secondary outcome variables was 
determined using a nonparametric, two-tailed Mann-Whitney U-test or the parametric 
Student’s t-test as appropriate. Categorical variables were compared using Chi2 or Fisher’s 
exact test as appropriate. Estimates of the effect size of the pregnancy intervention on 
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childhood asthma risk (primary outcome) were calculated as unadjusted odds ratio and 
obtained using logistic regression models. We also adjusted the models for sex, birth weight, 
rs8076131, rs8069176, rs9303277, rs7216389, rs2290400, and inhaled corticosteroid use 
prior to the first RCT screening visit because these variables were demonstrated previously to 
be associated with childhood asthma. In further explorative analyses, the estimates of the 
effect size of medications (ICS or LABA at screening visit, randomisation and last visit) on 
childhood asthma risk were also calculated as odds ratios and obtained using logistic 
regression models. These models were adjusted for sex, birth weight, rs8076131, rs8069176, 
rs9303277, rs7216389, and rs2290400. In order to investigate for interaction between 17q21 
variants and intervention interaction terms were included in the logistic regression analysis 
along with confounders. Predictor variables were tested for collinearity using variance 
inflation factors post estimation. The cut-off for statistical significance was set at 5% for all 
analyses. 
A causal mediation analysis (parametric regression approach described by 
VanderWeele(20),(21)) was used to decompose the effect of the FeNO intervention versus 
ICS use during pregnancy on childhood asthma. We considered “ICS use at any visit during 
the study” as a mediator (with a logistic regression model), as well as “time to first change in 
ICS dose” (imperfectly modelled as a linear regression since there are no methods capable of 
dealing with a censored time to event mediator variable). Smoking status was accounted for 
as a confounder of the mediator outcome relationship under the assumption that there are no 
unmeasured confounders of this relationship. We present the natural indirect effect (on the 
odds ratio scale), representing the effect what a treatment induced change in mediator has on 
asthma.  Standard errors and confidence intervals for the indirect effects were obtained via 
non-parametric bootstrapping (with n=500 replicates sampled with replacement); lower and 
upper bounds of the interval are presented as the 2.5th and 97.5th percentiles of the 
bootstrapped distribution. To complete the mediation analysis, we also assessed the 
associations of each path separately. The association between treatment group and any use of 
ICS was assessed using logistic regression; the association between treatment group and time 
from baseline to first change in ICS dose was assessed using discrete time survival analysis. 
The association between any ICS use (or time to first change in ICS dosage) and asthma was 
assessed using logistic regression. A Kaplan-Meier plot for the differences between treatment 
groups in time to first ICS dosage change is also provided. Hazard ratios (or odds ratios) with 
95% confidence intervals are presented. All analyses were programmed in Stata 13 
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(StataCorp, College Station Texas, USA) and plots were produced using Prism Graph 6 
(GraphPad software, La Jolla, USA).   
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Results 
Subject characteristics, prenatal and perinatal history 
140 children (78%) attended the follow-up visit between the ages of 4 and 6 years (mean age 
59 months, table 1). The intervention groups were balanced regarding the child’s sex, age, 
height and weight, allergic sensitisation and five 17q21 variants (table 1).  
Childhood asthma, respiratory symptoms and asthma management during pregnancy  
Prevalence of doctor diagnosed asthma was 36% (50/139) in this high-risk cohort. A 
significantly lower rate of asthma was observed in the offspring of mothers from the FeNO 
group, compared to the clinical management group (table 2, unadjusted OR 0.46, 95% CI 
0.22 to 0.96, p=0.037). The prevalences for wheeze ever, use of short acting beta agonists in 
the past 12 months, emergency department visits for wheezing or asthma in the last 12 
months, and frequent wheeze past 12 months were also significantly lower in the FeNO 
group (table 2). Significantly fewer children from the FeNO group had a past history of 
recurrent episodes of bronchiolitis at preschool age (table 2).  
Risk factors of childhood asthma 
Children diagnosed with asthma were less likely to be female and more likely to have a past 
history of bronchiolitis and a lower birth weight (table 3). Maternal ICS use at the screening, 
randomisation and final study visit reduced the odds ratio for childhood asthma (table 3, OR 
0.24, 0.35 and 0.46, p=0.002, 0.005 and 0.032, respectively). Average maternal FeNO levels 
during the RCT and FeNO levels at the final study visit were not significantly associated with 
childhood asthma (table 3). Doctor diagnosed asthma was significantly associated with risk 
alleles in the 17q21 variants rs8069176 and rs8076131 (table 3, OR 1.98 and 1.80, p=0.013 
and 0.033, respectively), as well as increased airway resistance at 5Hz and FeNO levels but 
not baseline FEV1 and lung clearance index in the children (Supplementary table 2). 
Childhood asthma, asthma management and ICS use during pregnancy  
In further explorative analyses we stratified the cohort into four groups of children based on 
the maternal asthma management group (FeNO or clinical) and the use of ICS (yes or no) at 
the RCT randomisation and final RCT visit (table 4). The highest prevalence of asthma was 
observed in those children whose mothers were in the clinical group and did not use ICS at 
randomisation or final study visit (reference group). The odds ratios for doctor diagnosed 
asthma (Fig 1 and table 4), wheeze ever, and short acting bronchodilator use in past 12 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
months (table 4) were significantly lower in children whose mothers were in the FeNO group 
and whose mothers were in the clinical group and using ICS.  
A causal mediation analysis was performed in order to determine to what extent the FeNO 
intervention caused a reduction in childhood asthma via “ICS use at any visit during the 
study” (natural indirect effect). This analysis confirmed a significant natural indirect effect of 
the FeNO intervention on asthma prevalence through “ICS use at any visit during the study” 
(OR 0.83; 95% CI 0.59 to 0.99). This amounts to approximately 30% of the total effect of 
FeNO intervention while the remainder was through other pathways. We hypothesized that 
the FeNO intervention may also have affected the time to the first change in ICS dose. This 
hypothesis was consistent with Kaplan-Meier estimates of survival probabilities for “time to 
first change in ICS dose” that showed that the clinical group had a significantly longer time to 
first change in ICS dose compared to the FeNO group (Fig 2, hazard ratio 1.87, 95% CI 1.22 
to 2.84, p=0.004). The natural indirect effect of FeNO intervention on childhood asthma 
through decreasing time to first ICS dosage change also appeared important in a subsequent 
causal mediation analysis (OR 0.90, 95% CI 0.70 to 1.03). The natural indirect effects of 
FeNO intervention through “ICS use at any visit during the study” and “time to first change 
in ICS dose” are consistent with Figure 1; among children who were born to women that did 
not use ICS the absolute difference between intervention groups in asthma prevalence was 
greater; among children who were born to women that did use ICS the absolute difference 
between intervention groups in asthma prevalence was smaller. 
Childhood asthma, 17q21 variants and maternal asthma management during pregnancy 
Asthma risk was significantly increased by risk alleles in all five 17q21 variants among those 
children (n=90) with a prior history of bronchiolitis in accordance with previous 
reports(7),(22) (Supplementary table 3 and Fig 3 for rs7216389). As expected, none of the 
17q21 risk alleles were associated with asthma in those children who never had bronchiolitis 
(n=78). These gene-environment interactions between bronchiolitis and risk alleles were 
significant for three out of the five 17q21 variants. We also found a significant association 
between risk alleles in three out of five 17q21 variants (rs2290400, rs9303277, rs7216389) 
and the expression patterns of ORMDL3 in PBMCs collected in our cohort (Fig 3 for 
rs7216389). Although bronchiolitis was a risk factor for childhood asthma (table 3) and 
recurrent bronchiolitis episodes were reduced in children from the FeNO group (table 2), we 
could not identify any significant interaction between any risk allele in the five 17q21 
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variants and the asthma management intervention during pregnancy (Supplementary table 3 
and Fig 3 for rs7216389).  
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Discussion 
The results of our study have demonstrated for the first time that FeNO-guided asthma 
management during pregnancy reduced the odds for doctor diagnosed asthma in preschool 
children. This intervention was also associated with a significantly reduced risk of frequent 
wheeze and recurrent bronchiolitis, and less medication use and emergency department visits 
for wheeze and asthma in the past 12 months prior to the follow up assessment.  
A strength of our study is the randomised, controlled design of the MAP study’s asthma 
management intervention along with comprehensive prospective data collection on asthma 
exacerbations, medications, and FeNO levels throughout pregnancy. Furthermore, our 
previously published studies on FeNO-guided asthma management in pregnancy and 
bronchiolitis risks in infancy provided a strong scientific rationale for the primary hypothesis 
to be tested in the GIA study(4). We acknowledge that a diagnosis of childhood asthma is 
considered more uncertain the younger the child is. However we demonstrated that childhood 
asthma diagnosed by the study doctor who was blinded to the mother’s pregnancy 
intervention was associated with common asthma risk factors and asthma-like symptoms, as 
well as with genetic variants at the 17q21 locus, increased airways resistance at 5Hz and 
elevated FeNO levels in our preschool cohort. We also confirmed previously described gene-
environment interactions at the 17q21 locus(7),(22) in an Australian cohort. Finally we 
provided functional evidence of variants at locus 17q21 resulting in differences in ORMDL3 
expression in a child cohort. This allowed us to demonstrate that FeNO-guided asthma 
management reduced the odds for childhood asthma independent of risk alleles for early-
onset asthma at the 17q21 locus. We found no evidence for a statistical interaction between 
17q21 variants in the offspring and FeNO guided management for the risk of asthma. It is 
possible however that a yet to be determined maternal genotype may interact with FeNO 
guided management to modify asthma risk. Bisgaard et al observed that supplementation of 
fish-oil derived fatty acids in pregnancy had a greater effect on wheeze and asthma 
development in children of mothers with a variant in the gene encoding fatty acid desaturase 
that was associated with lower blood levels of long-chain polyunsaturated fatty acids (23).  
A major effect of FeNO-guided asthma management during pregnancy was a reduction in 
asthma exacerbations during pregnancy, however this was not associated with childhood 
asthma risk (table 3). We reported previously(3) that FeNO-guided asthma management also 
resulted in an increase in ICS and ICS/LABA use during pregnancy. Therefore it was not 
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unexpected to find a decrease in childhood asthma risk if the mother used ICS (table 3). 
However, we also found that ICS use at the RCT screening visit -that represents pregnancy 
exposure prior to any intervention- showed a strong inverse relationship with childhood 
asthma prevalence (OR 0.24, 95% CI 0.10 to 0.59, p=0.002). This raised the possibility that 
some of the benefit of the FeNO intervention on childhood asthma may have been mediated 
by more appropriate ICS use during pregnancy, which was supported by a causal mediation 
analysis. We also found that time to first change in ICS dose was significantly reduced in the 
FeNO group compared to the control group (Fig 3). Time to first change in ICS was probably 
also an important effect mediator, further highlighting the complex effects that FeNO-guided 
asthma management algorithm had on the use of ICS in pregnancy.  
Furthermore, ICS use at the final RCT visit was associated with a lower asthma risk in the 
clinical group (Fig 1). This suggests that there may be a potential beneficial effect of ICS 
therapy in pregnancy for reducing childhood asthma risk. We propose that FeNO-guided 
asthma management resulted in an optimised monthly treatment decision regarding the use 
and dose of ICS by considering Th2 cytokine-induced airway inflammation along with 
clinical symptoms. Importantly, our results provide long-term child health outcomes to 
further support the clinical consensus that the benefits of ICS therapy in pregnancy -when 
used guided by FeNO levels and clinical symptoms- largely outweigh their potential risks.  
FeNO-guided management and ICS maintenance treatment may have resulted in reduced Th2 
inflammation during pregnancy and led to changes at the feto-maternal interface that 
suppressed the development of asthma in early childhood. We previously showed that asthma 
during pregnancy resulted in differential methylation profiles in the infant’s blood DNA(24). 
Epigenetic changes may have affected airway growth, lung repair and regeneration, or the 
child’s immune response. Interestingly, we found no effect of the pregnancy intervention on 
atopy suggesting changes that are independent of the child’s IgE-mediated immune response.    
Our study has limitations. Firstly, despite good participation, our cohort is small however the 
effect size large and significant in this high-risk cohort. Our results will however enable the 
design of future appropriately powered RCTs for other outcomes, for instance airway 
resistance at 5Hz and FeNO levels between the intervention groups that were associated with 
childhood asthma in our study. In this regard, we are currently conducting the multi-centre 
Breathing for Life RCT  (Australian and New Zealand Clinical Trials Registry number 
12613000202763) to test the effect of FeNO-guided asthma management on perinatal 
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outcomes (primary outcome) and have begun a stage 2 paediatric follow-up study to 
determine pre-specified childhood outcomes informed by the GIA study(25). A blinded study 
doctor who took into account parent reported symptoms made the diagnosis of asthma. This 
can be inaccurate in preschool age although it should have affected both groups equally as 
mothers and staff remain blinded. In accordance, we found no difference in the association 
between 17q21 variants and childhood asthma in children from the clinical and FeNO group. 
Fewer children from the FeNO group participated in the follow-up visit. Investigating the 
reasons for non-participating at the preschool follow-up visit revealed that more children 
from the FeNO versus clinical group moved out of the area (14 versus 5 children, 
respectively) and more did not attend the visit despite scheduling appointments trice (6 versus 
2 children) (Supplement Figure 1). We have conducted phone interviews with the parents of 
children who were unable to attend the follow-up visit but consented to provide information 
by phone. We could get in contact with 15 parents after attempting on at least three separate 
occasions. The interviewer and parent remained fully blinded regarding treatment group 
allocation. The prevalence for doctor diagnosed asthma in the clinical group was 40% (2 out 
of 5) and in the FeNO group, it was 30% (3 out of 10). When reanalysing the results with all 
children included, we confirmed a significantly lower rate of doctor diagnosed asthma in the 
offspring of mothers from the FeNO group, compared to the clinical management group 
(unadjusted OR 0.497, 95% CI  0.229 to 0.989, p=0.047, n=154). This data further helps to 
assure that there is no attrition bias.  
Our study has important clinical implications because asthma is the most common chronic 
disease to affect pregnant women, making improvements in this area clinically relevant for a 
significant number of women and their children. We have demonstrated that management of 
asthma during pregnancy with a FeNO-guided strategy, which adjusted treatment according 
to both symptoms and airway inflammation, reduced the odds of asthma at the age of 4-6 
years of age by over 50%. Implementation of this approach in clinical practice has the 
potential to reduce asthma rates among a group of children at high-risk of developing the 
disease.   
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Contributors 
MM and Joseph Meredith collected data. Joerg Mattes (JM), PGG, VM were responsible for 
the concept outline, study design, ethics application, funding applications, team meetings, 
data collection, data interpretation. JM and MM prepared first draft of the manuscript. AC 
was responsible for the processing and secure storage of re-identifiable bio-specimens, 
contributed to the study design, data collection and data interpretation. PDR, PDS advised 
regarding the study design, study methodology, data collection, and provided data 
interpretation. HP managed data sets, merged data sets, and prepared data for statistical 
analysis. DB, CO performed statistical analyses. MM and JM prepared tables and figures. JA 
advised and supervised parts of the statistical analysis. All authors interpreted data, edited 
and critically reviewed all manuscript drafts. 
Declarations of interests 
No author has any competing interests to declare. 
Acknowledgements 
We wish to thank and acknowledge Kathryn Jesson, Kelly Steel, and Dr Ana Pereira de 
Siqueira for their invaluable assistance with this research project. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
References 
1. Lim RH, Kobzik L, Dahl M. Risk for asthma in offspring of asthmatic mothers versus fathers: a 
meta-analysis. PLoS One. 2010;5(4):e10134. 
2. Martel MJ, Rey E, Beauchesne MF, Malo JL, Perreault S, Forget A, et al. Control and severity 
of asthma during pregnancy are associated with asthma incidence in offspring: two-stage case-
control study. Eur Respir J. 2009;34(3):579-87. 
3. Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, et al. Management of 
asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, 
randomised controlled trial. Lancet. 2011;378(9795):983-90. 
4. Mattes J, Murphy VE, Powell H, Gibson PG. Prenatal origins of bronchiolitis: protective effect 
of optimised asthma management during pregnancy. Thorax. 2014;69(4):383-4. 
5. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing 
rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit 
Care Med. 2008;178(7):667-72. 
6. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, 
consortium-based genomewide association study of asthma. N Engl J Med. 2010;363(13):1211-21. 
7. Caliskan M, Bochkov YA, Kreiner-Moller E, Bonnelykke K, Stein MM, Du G, et al. Rhinovirus 
wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med. 2013;368(15):1398-407. 
8. Miller M, Tam AB, Cho JY, Doherty TA, Pham A, Khorram N, et al. ORMDL3 is an inducible 
lung epithelial gene regulating metalloproteases, chemokines, OAS, and ATF6. Proc Natl Acad Sci U S 
A. 2012;109(41):16648-53. 
9. Miller M, Rosenthal P, Beppu A, Mueller JL, Hoffman HM, Tam AB, et al. ORMDL3 transgenic 
mice have increased airway remodeling and airway responsiveness characteristic of asthma. J 
Immunol. 2014;192(8):3475-87. 
10. Loser S, Gregory LG, Zhang Y, Schaefer K, Walker SA, Buckley J, et al. Pulmonary ORMDL3 is 
critical for induction of Alternaria-induced allergic airways disease. J Allergy Clin Immunol. 2016. 
11. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment 
of health related quality of life in asthma: development of a questionnaire for use in clinical trials. 
Thorax. 1992;47(2):76-83. 
12. Juniper EF, Bousquet J, Abetz L, Bateman ED, Committee TG. Identifying 'well-controlled' and 
'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2006;100:616-21. 
13. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of 
Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995;8(3):483-91. 
14. Strippoli MP, Silverman M, Michel G, Kuehni CE. A parent-completed respiratory 
questionnaire for 1-year-old children: repeatability. Arch Dis Child. 2007;92(10):861-5. 
15. Powell CV, McNamara P, Solis A, Shaw NJ. A parent completed questionnaire to describe the 
patterns of wheezing and other respiratory symptoms in infants and preschool children. Arch Dis 
Child. 2002;87(5):376-9. 
16. Australia NAC. Australian Asthma Handbook, Version 1.2. National Asthma Council Australia, 
Melbourne, 2016. Available from: http://wwwasthmahandbookorgau. 2016. 
17. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, et al. Consensus statement 
for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J. 
2013;41(3):507-22. 
18. American Thoracic S, European Respiratory S. ATS/ERS recommendations for standardized 
procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and 
nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912-30. 
19. Bouzigon E, Corda E, Aschard H, Dizier MH, Boland A, Bousquet J, et al. Effect of 17q21 
variants and smoking exposure in early-onset asthma. N Engl J Med. 2008;359(19):1985-94. 
20. VanderWeele TJ. On the distinction between interaction and effect modification. 
Epidemiology. 2009;20(6):863-71. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21. VanderWeele TJ. Marginal structural models for the estimation of direct and indirect effects. 
Epidemiology. 2009;20(1):18-26. 
22. Loss GJ, Depner M, Hose AJ, Genuneit J, Karvonen AM, Hyvarinen A, et al. The Early 
Development of Wheeze. Environmental Determinants and Genetic Susceptibility at 17q21. Am J 
Respir Crit Care Med. 2016;193(8):889-97. 
23. Bisgaard H, Stokholm J, Chawes BL, Vissing NH, Bjarnadottir E, Schoos AM, et al. Fish Oil-
Derived Fatty Acids in Pregnancy and Wheeze and Asthma in Offspring. N Engl J Med. 
2016;375(26):2530-9. 
24. Gunawardhana LP, Baines KJ, Mattes J, Murphy VE, Simpson JL, Gibson PG. Differential DNA 
methylation profiles of infants exposed to maternal asthma during pregnancy. Pediatric 
pulmonology. 2013. 
25. Murphy VE, Jensen ME, Mattes J, Hensley MJ, Giles WB, Peek MJ, et al. The Breathing for 
Life Trial: a randomised controlled trial of fractional exhaled nitric oxide (FENO)-based management 
of asthma during pregnancy and its impact on perinatal outcomes and infant and childhood 
respiratory health. BMC pregnancy and childbirth. 2016;16:111. 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 1: Odds ratio and 95% confidence intervals (CI) adjusted for sex, birth weight, 
rs8076131, rs8069176 for childhood asthma stratified for double-blind asthma management 
intervention during pregnancy and A) ICS use (yes [+] or no [-]) at randomisation and B) ICS 
at last RCT visit. *p<0.05 
Figure 2: Kaplan-Meir estimates of survival probabilities in FeNO (red) versus clinical (blue) 
group for time to first change in ICS dose (hazard ratio 1.87, 95% CI 1.22 to 2.84, p=0.004). 
First visit (“0”) is screening visit and second visit (“1”) is randomisation visit.  
Figure 3: Prevalence of childhood asthma stratified for A) a past history of bronchiolitis or B) 
double-blind asthma management intervention during pregnancy by rs7216389 alleles 
(C=cytosine; T=thymidine [risk allele]). C) ORDML3 expression in PBMCs by rs7216389 
alleles. 
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Table 1: Subject characteristics, prenatal/perinatal history by pregnancy intervention in 
the GIA cohort 
 
Data shown as median ± IQR or mean ± standard error of mean for normally distributed datasets 
unless otherwise indicated 
 
 Clinical FeNO 
Total (n=140) 81 59 
Female 43/81 (53%) 31/59 (53%) 
Age (months) 56  ±10 57 ±9  
Mean weight (kg)  19·42 ± 0·30 20·02 ± 0·49 
Mean height (cm) 109·2 ± 0·74 110·0 ± 0·99 
Atopy (Skin prick test positive <3mm) 21/81 (26%) 15/58 (26%) 
Exclusive breastfeeding (weeks) 14 ±24  18 ±21 
Prematurity (<37 weeks) 8/81 (10%) 3/59 (6%) 
Birth weight (kg) 3·28± 0·07 3·51 ± 0·07 
Caesarean section elective 16/78 (21%) 5/56 (9%) 
Caesarean section non-elective 10/78 (13%) 8/56 (14%) 
rs8069176 (CC) 
                   (CG) 
                   (GG) 
14/80 (17·5%) 
40/80 (50·0%) 
26/80 (32·5%) 
9/58 (15·5%) 
26/58 (44·8%) 
23/58 (39·7%) 
rs8076131 (TT) 
                   (TA) 
                   (AA) 
11/80 (13·8%) 
40/80 (50·0%) 
29/80 (36·3%) 
12/58 (20·7%) 
30/58 (51·7%) 
16/58 (27·6%) 
rs2290400 (TT) 
                   (TA) 
                   (AA) 
16/80 (20·0%) 
38/80 (47·5%) 
26/80 (32·5%) 
13/58 (22·4%) 
26/58 (44·8%) 
19/58 (32·8%) 
rs9303277 (GG) 
                   (CG) 
                   (CC) 
1/80 (1·3%) 
53/80 (66·3%) 
26/80 (32·5%) 
5/58 (8·6%) 
35/58 (60·3%) 
18/58 (31·0%) 
rs7216389 (TT) 
                   (TA) 
                   (AA) 
16/80 (20·0%) 
38/80 (47.5%)  
26/80 (32·5%) 
13/58 (24·4%)  
29/58 (50·0%) 
16/58 (27·6%) 
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Table 2: Doctor diagnosed asthma, asthma-associated symptoms and bronchiolitis in the GIA cohort stratified for maternal 
asthma management during pregnancy 
 Clinical group 
n/N (%) 
FeNO group 
n/N (%) 
Unadjusted OR 
(95% CI) 
Adjusted OR (95% 
CI)* 
Doctor diagnosed asthma 35/81 (43·2%) 15/58 (25·9%) 0·46 (0·22 to 0·96) 
p=0·037 
0·39 (0·16 to 0·94) 
p=0·035 
Has your child ever had wheezing or 
whistling in the chest at any time in the 
past? 
53/81 (65·4%) 28/58 (48·3%) 0·49 (0·25 to 0·98) 
p=0·044 
0·45 (0·20 to 1.01) 
p=0·052 
Short-acting beta agonist use in the last 12 
months to manage cough, wheeze or asthma 
48/79 (61·0%) 23/56 (41·1%) 0·49 (0·25 to 0·97) 
p=0·042 
0·41 (0·18 to 0·93) 
p=0·033 
Attending the emergency department in the 
last 12months for wheezing or asthma 
14/65 (21·5%) 2/55 (3·6%) 0·17 (0·04 to 0·76) 
p=0·021 
0·15 (0·03 to 0·76) 
p=0·023 
Frequent wheeze in the last 12 months 
(greater than four episodes) 
18/81 (22·2%) 4/58 (6·9%) 0·27 (0·09 to 0·87) 
p=0·027 
0·24 (0·06 to 0·88) 
p=0·032 
Bronchiolitis ever 35/77 (45·5%) 18/55 (32·7%) 0·60 (0·29 to 1·24) 
p=0·167 
0·59 (0·27 to 1·29) 
p=0·186 
Frequent bronchiolitis (more than one 
episode)  
21/77 (27·3%) 4/55 (7·3%) 0·21 (0·07 to 0·65) 
p=0·007 
0·15 (0·04 to 0·54) 
p=0·004 
P values and odds ratios were calculated using unadjusted and adjusted logistic regression models 
*adjusted for gender, birth weight, rs8076131, rs8069176, rs9303277, rs7216389, rs2290400, visit 1 ICS use 
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Table 3: Asthma risk in the GIA cohort according to demographics, genetic risk and 
perinatal history 
 Asthmatic Non Asthmatic Unadjusted OR (95% 
CI) 
Female 21/50 (42·0%) 53/89 (59·6%) 0·49 (0·24 to 0·99) 
p=0·048 
Atopy (Skin prick test positive 
<3mm) 
17/50 (34·0%) 19/89 (21·3%) 1·90 (0·88 to 4·12) 
p=0·105 
Birth weight (grams) 3194 ± 101·42 3462± 60·77 1·00 (0·99 to 1·00) 
p=0·024 
Bronchiolitis ever 29/48 (60·4%) 25/85 (29·4%) 3·66 (1·74 to 7·70) 
p=0·001 
Frequent bronchiolitis (more than 
one episode)  
20/48 (41·7%) 6/85 (7·1%) 9·40 (3·43 to 25·80) 
p<0·0001 
Maternal self-reported smoking 
during pregnancy 
5/49 (8·5%) 10/89 (11·2%) 0·90 (0·29 to 2·79) 
p=0·852 
Asthma exacerbation during 
pregnancy 
23/49 (46·9%) 37/89 (41·5%) 1·24 (0·62 to 2·51) 
p=0·543 
Maternal ICS use at screening 
(first) visit 
7/50 (14·0%) 36/89 (40·4%) 0·24 (0·10 to 0·59) 
p=0·002 
Maternal ICS use at 
randomisation (second) visit 
16/50 (32·0%) 51/89 (57·3%) 0·35 (0·17 to 0·73) 
p=0·005 
Maternal ICS use final visit 22/50 (44·0%) 56/89 (62·9%) 0·46 (0·23 to 0·94) 
p=0·032 
Maternal ICS+LABA use at at 
screening (first) visit 
7/50 (14·0%) 25/89 (28·1%) 0·42 (0·17 to 1·05) 
p=0·063 
Maternal ICS+LABA use at 
randomisation (second) visit 
10/50 (20·0%) 28/89 (31·4%) 0·54 (0·24 to 1·24) 
p=0·149 
Maternal ICS+LABA use final 
visit 
11/50 (22·0%) 33/89 (37·1%) 0·48 (0·22 to 1·06) 
p=0·069 
Mean maternal FeNO (ppb) 11·32 ±21 11·35 ±13·62 1·00 (0·99 to 1·03) 
p=0·487 
Maternal FeNO final visit (ppb) 8 ±16·5 8·2 ±8·7 1·01 (0·99 to 1·04) 
p=0·183 
rs8069176 (CC) 
                   (CG) 
                   (GG) 
6/23 (26·1%) 
17/65 (26·2%) 
25/49 (51·0%) 
17/23 (73·9%) 
48/65 (73·8%) 
24/49 (49·0%) 
1·98 (1·16 to 3·41) 
p=0·013 
rs8076131 (TT) 
                   (TA) 
                   (AA) 
4/23 (17·4%) 
24/69 (34·8%) 
20/45 (44·4%) 
19/23 (82·6%) 
45/69 (65·2%) 
25/45 (55·5%) 
1·80 (1·05 to 3·09) 
p=0·033 
rs2290400 (TT) 
                   (TA) 
                   (AA) 
8/29 (27·6%) 
21/63 (33·3%) 
19/45 (34·5%) 
21/29 (72·4%) 
42/63 (66·6%) 
36/45 (65·5%) 
1·40 (0·85 to 2·29) 
p=0·185 
rs9303277 (GG) 
                   (CG) 
                   (CC) 
1/6 (16·7%) 
28/87 (32·1%) 
19/44 (43·2%) 
5/6 (83·3%) 
59/87 (67·8%) 
25/44 (56·8%) 
1·69 (0·87 to 3·29) 
p=0·120  
rs7216389 (TT) 
                   (TA) 
                   (AA) 
8/29 (27·6%) 
22/67 (32·8%)  
18/42 (42·9%) 
21/29 (72·4%)  
45/67 (67·2%) 
24/42 (57·1%) 
1·42 (0·86 to 2·34) 
p=0·174 
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Data shown as median ± IQR or mean ± standard error of mean for normally distributed datasets 
unless otherwise indicated 
P values and odds ratios were calculated using unadjusted logistic regression models 
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Table 4: Childhood asthma prevalence stratified for ICS use at randomisation visit and for maternal asthma management group 
 
P values and odds ratios were calculated using adjusted logistic regression models 
*adjusted for gender, birth weight, rs8076131, rs8069176, rs9303277, rs7216389, rs2290400 
 
ICS use at randomisation visit 
 Clinical/No ICS  
(N=40) 
Clinical/ICS 
(N=41) 
FeNO/No ICS 
(N=31) 
FeNO/ICS (N=28) χ2 
Doctor diagnosed asthma 24/41 (59%) 
Reference 
11/40 (28%)          
0·19 (0·06 to 0·56) 
p=0·003 
10/31 (32%)           
0·28 (0·09 to 0·87) 
p=0·028 
5/27 (19%)            
0·14 (0·04 to 0·50) 
p=0·003 
0·003 
Has your child ever had wheezing or 
whistling in the chest at any time in 
the past? 
32/41 (78%) 
Reference 
21/40 (52%)          
0·24 (0·08 to 0·71) 
p=0·010 
14/30 (47%)          
0·22 (0·07 to 0·71) 
p=0·011 
14/28 (50%)          
0·26 (0·08 to 0·83) 
p=0·023 
0·019 
Short-acting beta agonist use in the 
last 12 months to manage cough, 
wheeze or asthma 
31/40 (78%) 
Reference 
17/39 (44%)          
0·20 (0·07 to 0·60) 
p=0·004 
14/30 (47%)          
0·25 (0·08 to 0·79) 
p=0·018 
9/28 (32%)            
0·15 (0·05 to 0·49) 
p=0·002 
0·001 
ICS use at final visit 
 Clinical/No ICS 
(N=47) 
Clinical/ICS 
(N=34) 
FeNO/No ICS 
(N=14) 
FeNO/ICS (N=44) χ2 
Doctor diagnosed asthma 25/47 (53%) 
Reference 
10/34 (29%)          
0·23 (0·08 to 0·69) 
p=0·009 
3/14 (21%)            
0·16 (0·03 to 0·90) 
p=0·038 
12/44 (27%)          
0·28 (0·10 to 0·77) 
p=0·013 
0·028 
Has your child ever had wheezing or 
whistling in the chest at any time in 
the past? 
34/47 (72%) 
Reference 
19/34 (56%) 
0·37 (0·13 to 1.00) 
p=0·051 
6/14 (43%) 
0·27 (0·07 to 1·10) 
p=0·068 
22/44 (50%) 
0·36 (0·14 to 0·93) 
p=0·035 
0·084 
Short acting beta agonist use in the 
last 12 months to manage cough, 
wheeze or asthma 
34/46 (74%) 
Reference                
14/33 (42%)                 
0·18 (0·06 to 0·52) 
p=0·002 
4/14 (29%)                    
0·11 (0·02 to 0·55) 
p=0·007 
19/44 (43%) 
 0·24 (0·09 to 
0·66) p=0·005 
0·002 
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Supplementary Figure 1: Recruitment and participation of the GIA cohort (DNA, did not attend) 
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Supplementary Table 1: Primer list 
Transcript Direction Primer Sequence 
 
ORMDL3 
Forward 5’-CAC CAA CCT CAT TCA CAA CA -3’ 
Reverse 5’-AAG TAC AGC ACG ATG GGT GT-3’ 
 
HPRT 
Forward 5’-TGA CAC TGG CAA AAC AAT GCA-3’ 
Reverse 5’-GGT CCT TTT CAC CAG CAA GCT-3’ 
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Supplementary Table 2: Lung function according to asthma in GIA cohort 
 Asthmatic Non Asthmatic Unadjusted OR (95% CI) 
Zscore Resistance at 5Hz (N=109)  
 
0·69 ± 0·19 0·19 ± 0·11 1·64 (1·07 to 2·51) p=0·024 
Lung clearance index (N=96) 
 
7·33 ± 0·14 7·22 ± 0·10 1·19 (0·71 to 1·94) p=0·539 
Fraction of exhaled nitric oxide (ppb) (N=51) 
 
5·07 ± 13·63 3·97 ± 3·33 1·12 (1·01 to 1·25) p=0·028 
FEV1% predicted (N=79) 107.44 ± 14·97 110.36 ± 13·17 0·98 (0·95 to 1·02) p=0·36 
FEV1/FVC % predicted (N=79) 102.10 ± 9.17 104.68 ± 8.37 0·97 (0·92 to 1·02) p=0·20 
P values and odds ratios were calculated using unadjusted logistic regression models 
Data shown as median ± IQR or mean ± standard error of mean for normally distributed datasets 
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Supplementary Table 3: Association between doctor diagnosed asthma and 17q21 variants stratified for a past history of bronchiolitis 
and maternal asthma management during pregnancy 
SNP 
 
OR (95% CI) for doctor diagnosed asthma* 
Past history of bronchiolitis (Yes versus No) Asthma management (Clinical versus FeNO) 
Yes (N=51) No (N=78) Interaction     
p value 
Clinical group (N=80) FeNO group 
(N=57) 
Interaction      
p value 
rs7216389  3·38 (1·29 to 8·80) 
p=0·013 
0·87 (0·39 to 1·92) 
p=0·729 
0·029 1·47 (0·71 to 3·06) 
p=0·298 
1·37 (0·54 to 3·48) 
p=0·513 
0·832 
rs9303277 6·75 (1·53 to 29·88) 
p=0·012 
0·87 (0·32 to 2·35) 
p=0·775 
0·021 1·44 (0·51 to 4·04) 
p=0·494 
2·07 (0·65 to 6·59) 
p=0·219 
0·687 
rs2290400 3·41 (1·33 to 8·77) 
p=0·011 
0·72 (0·32 to 1·60) 
p=0·423 
0·012 1·46 (0·70 to 3·05) 
p=0·309 
1·40 (0·56 to 3·51) 
p=0·468 
0·845 
rs8076131 3·18 (1·21 to 8·30) 
p=0·018 
1·10 (0·46 to 2·60) 
p=0·834 
0·094 1·43 (0·67 to 3·12) 
p=0·367 
1·98 (0·74 to 5·28) 
p=0·175 
0·718 
rs8069176 2·64 (1·09 to 6·39) 
p=0·031 
1·29 (0·57 to 2·95) 
p=0·540 
0·223 2·11 (0·98 to 4·53) 
p=0·055 
3·07 (1·03 to 9·14) 
p=0·044 
0·571 
P values and odds ratios were calculated using adjusted logistic regression models 
*adjusted for gender, birth weight, visit 1 ICS use 
